5‐HT 4 receptor‐mediated modulation of 5‐HT release in the rat hippocampus in vivo

5‐HT 4 receptor‐mediated modulation of 5‐HT release in the rat hippocampus in vivo 1 In the present study, the ability of the 5‐hydroxytryptamine4 receptor (5‐HT4 receptor) to modulate the release of 5‐HT in the hippocampus of freely‐moving rats was investigated by the in vivo microdialysis technique. 2 The 5‐HT4 receptor agonist, renzapride (1.0–100 μm, administered via the microdialysis probe) increased extracellular hippocampal levels of 5‐HT in a concentration‐dependent manner (approximately 200% maximal increase). The ability of renzapride (100 μm, administered via the microdialysis probe) to elevate extracellular levels of 5‐HT remained in the presence of the selective 5‐HT reuptake blocker, paroxetine (1.0 μm, administered via the microdialysis probe). Furthermore, another 5‐HT4 receptor agonist 5‐methoxytryptamine (5‐MeOT; 10 μm, administered via the microdialysis probe, in the presence of the non‐5‐HT4 5‐HT receptor antagonists pindolol (10 μm) and methysergide (10 μm)) maximally elevated extracellular levels of 5‐HT by approximately 450% in the rat hippocampus. The elevation of extracellular 5‐HT levels induced by either renzapride (100 μm) or 5‐MeOT (10 μm) was completely prevented by combined administration of the selective 5‐HT4 receptor antagonist, GR113808 (100 nM, administered via the microdialysis probe). GR113808 (100 nM, administered via the microdialysis probe) administered alone, however, reduced extracellular hippocampal 5‐HT levels by some 60%. 3 Systemic administration of the 5‐HT1A receptor agonist, 8‐OH‐DPAT (0.1 mg kg−1, s.c.) reduced extracellular levels of 5‐HT in the rat hippocampus by approximately 40%. Prior administration of 8‐OH‐DPAT (0.1 mg kg−1, s.c.), with an associated reduction of extracellular hippocampal 5‐HT levels by approximately 40–50%, however, failed to prevent a subsequent elevation of extracellular levels of 5‐HT induced by renzapride (100 μm, administered via the microdialysis probe). 4 Systemic administration of the 5‐HT4 receptor agonist, renzapride (0.25 and 1.0 mg kg−1, i.p.) increased extracellular levels of 5‐HT in the hippocampus in a dose‐dependent manner. The higher dose of renzapride increasing extracellular 5‐HT levels by some 200%. The selective 5‐HT4 receptor antagonist, GR125487D (1.0–100 μg kg−1, i.p.) caused a dose‐dependent reduction in extracellular levels of 5‐HT in the hippocampus (maximally approximately 80% reduction). Prior administration of GR125487D (10 μg kg−1, i.p.) prevented the elevation of extracellular levels of 5‐HT induced by renzapride (1.0 mg kg−1, i.p.). 5 In conclusion, the present study provides evidence that activation of the 5‐HT4 receptor facilitates 5‐HT release in the rat hippocampus in vivo. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Pharmacology Wiley

5‐HT 4 receptor‐mediated modulation of 5‐HT release in the rat hippocampus in vivo

Loading next page...
 
/lp/wiley/5-ht-4-receptor-mediated-modulation-of-5-ht-release-in-the-rat-M1If0Rd0DH
Publisher
Wiley
Copyright
1996 British Pharmacological Society
ISSN
0007-1188
eISSN
1476-5381
DOI
10.1111/j.1476-5381.1996.tb15309.x
Publisher site
See Article on Publisher Site

Abstract

1 In the present study, the ability of the 5‐hydroxytryptamine4 receptor (5‐HT4 receptor) to modulate the release of 5‐HT in the hippocampus of freely‐moving rats was investigated by the in vivo microdialysis technique. 2 The 5‐HT4 receptor agonist, renzapride (1.0–100 μm, administered via the microdialysis probe) increased extracellular hippocampal levels of 5‐HT in a concentration‐dependent manner (approximately 200% maximal increase). The ability of renzapride (100 μm, administered via the microdialysis probe) to elevate extracellular levels of 5‐HT remained in the presence of the selective 5‐HT reuptake blocker, paroxetine (1.0 μm, administered via the microdialysis probe). Furthermore, another 5‐HT4 receptor agonist 5‐methoxytryptamine (5‐MeOT; 10 μm, administered via the microdialysis probe, in the presence of the non‐5‐HT4 5‐HT receptor antagonists pindolol (10 μm) and methysergide (10 μm)) maximally elevated extracellular levels of 5‐HT by approximately 450% in the rat hippocampus. The elevation of extracellular 5‐HT levels induced by either renzapride (100 μm) or 5‐MeOT (10 μm) was completely prevented by combined administration of the selective 5‐HT4 receptor antagonist, GR113808 (100 nM, administered via the microdialysis probe). GR113808 (100 nM, administered via the microdialysis probe) administered alone, however, reduced extracellular hippocampal 5‐HT levels by some 60%. 3 Systemic administration of the 5‐HT1A receptor agonist, 8‐OH‐DPAT (0.1 mg kg−1, s.c.) reduced extracellular levels of 5‐HT in the rat hippocampus by approximately 40%. Prior administration of 8‐OH‐DPAT (0.1 mg kg−1, s.c.), with an associated reduction of extracellular hippocampal 5‐HT levels by approximately 40–50%, however, failed to prevent a subsequent elevation of extracellular levels of 5‐HT induced by renzapride (100 μm, administered via the microdialysis probe). 4 Systemic administration of the 5‐HT4 receptor agonist, renzapride (0.25 and 1.0 mg kg−1, i.p.) increased extracellular levels of 5‐HT in the hippocampus in a dose‐dependent manner. The higher dose of renzapride increasing extracellular 5‐HT levels by some 200%. The selective 5‐HT4 receptor antagonist, GR125487D (1.0–100 μg kg−1, i.p.) caused a dose‐dependent reduction in extracellular levels of 5‐HT in the hippocampus (maximally approximately 80% reduction). Prior administration of GR125487D (10 μg kg−1, i.p.) prevented the elevation of extracellular levels of 5‐HT induced by renzapride (1.0 mg kg−1, i.p.). 5 In conclusion, the present study provides evidence that activation of the 5‐HT4 receptor facilitates 5‐HT release in the rat hippocampus in vivo.

Journal

British Journal of PharmacologyWiley

Published: Apr 1, 1996

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off